logo

NUVB

Nuvation Bio·NYSE
--
--(--)
--
--(--)
4.83 / 10
Netural

NUVB's fundamentals score 4.8/10, indicating fair but not strong financial health. Constructive elements include a solid interest-coverage ratio (15.48%) and positive Profit-MV, while weaknesses such as high Days sales outstanding (135 days) and negative Revenue-MV (-2.57) temper the outlook. Overall, the company presents a balanced risk-reward profile.

Fundamental(4.83)SentimentTechnical

Analysis Checks(8/10)

Revenue-MV
Value-2.57
Score1/3
Weight8.13%
1M Return4.24%
Total operating revenue (YoY growth rate %)
Value873.03
Score2/3
Weight1.73%
1M Return1.11%
Days sales outstanding
Value135.05
Score0/3
Weight-7.15%
1M Return-5.18%
Profit-MV
Value0.46
Score2/3
Weight16.14%
1M Return8.45%
Net income-Revenue
Value-0.17
Score2/3
Weight16.16%
1M Return8.45%
PB-ROE
Value1.04
Score2/3
Weight20.13%
1M Return9.14%
Interest coverage ratio (EBIT / Interest expense) (%)
Value15.48
Score2/3
Weight-1.61%
1M Return-1.11%
Operating revenue (YoY growth rate %)
Value873.03
Score2/3
Weight0.67%
1M Return0.43%
Asset-MV
Value-0.50
Score3/3
Weight29.93%
1M Return13.15%
Cash-MV
Value-0.07
Score2/3
Weight15.87%
1M Return8.41%
Is NUVB undervalued or overvalued?
  • NUVB scores 4.83/10 on fundamentals and holds a Fair valuation at present. Backed by its -42.56% ROE, -813.07% net margin, -8.99 P/E ratio, 6.00 P/B ratio, and 77.52% earnings growth, these metrics solidify its Netural investment rating.